Viewpoint welcomes short papers expressing a personal opinion on matters of general interest to statisticians in the pharmaceutical industry. In this first issue Professor Stephen Senn shares his views on the authorship of drug industry trials.
No takes yet. Share an insight, caveat, or question.
Stephen Senn (2002) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: